Main Side Effects of 5-α-Reductase Inhibitors (Finasteride) in Women
In women using finasteride for hair loss or hirsutism, the most commonly reported side effects are headache and mild depression during the first month of treatment, with very few sexual side effects reported—a stark contrast to the 2–4% rate of sexual dysfunction seen in men. 1, 2, 3
Key Safety Profile in Women
Most Common Adverse Effects
- Headache and mild depression occur primarily during the first month of treatment and are typically of modest severity 4
- Libido changes are notably absent in women treated with finasteride, unlike the decreased libido reported in 2–4% of men 4, 5
- Gastrointestinal discomfort has been reported in some women 3
- Isolated reports of menstrual changes, acne, and dizziness exist but are uncommon 3
Sexual Function Effects
- Multiple studies in women with hirsutism treated with finasteride for 3–12 months found no modification of libido during therapy 4, 5, 6
- A systematic review of 20 peer-reviewed articles found that very few side effects related to sexual function have been reported in studies using finasteride to treat hair loss in women 2
- This represents a striking difference from men, where erectile dysfunction, decreased libido, and reduced ejaculate volume occur in 2–15.8% of patients 3, 7
Critical Teratogenic Risk (Most Important Safety Concern)
- Finasteride is absolutely contraindicated in pregnancy because it causes abnormalities of external genitalia in male fetuses 8, 9
- Pregnant women or those who may become pregnant must not handle crushed or broken tablets; if contact occurs, wash the area immediately with soap and water 8
- Strict contraception is mandatory for all women of reproductive age during treatment and for ≥30 days after discontinuation 9, 10
- This teratogenic risk is the single most important safety consideration and must be emphasized repeatedly during counseling 9
Hormonal Changes (Not Clinically Problematic)
- Dihydrotestosterone (DHT) levels decrease significantly during treatment, as expected from the mechanism of action 4, 5
- Testosterone levels increase significantly after 3–6 months of treatment 4, 5
- No changes occur in LH, FSH, estradiol, androstenedione, DHEAS, or sex hormone-binding globulin (SHBG) 4, 5
- Cortisol levels may transiently decrease after 1 month but return to baseline by 3 months 5
Long-Term Tolerability
- Finasteride is well tolerated in long-term treatment (12 months) of women with idiopathic hirsutism, with no significant adverse effects reported 6
- No hepatotoxicity has been reported in women, unlike the rare but serious liver toxicity seen with flutamide (another antiandrogen) 1
Psychiatric Effects: Emerging Concerns (Primarily in Men)
- Recent data from FDA adverse event reports show an upward trend in suicidality-related safety signals among finasteride users, peaking in 2024, though this data is predominantly from young male users 11
- A meta-analysis found that depression risk is elevated with finasteride (odds ratio 2.14), and suicidal ideation or behavior was reported in 21.2% versus 14.0% without finasteride—but again, these data are primarily from male populations 12
- In women specifically, only mild depression of modest severity during the first month has been documented in clinical trials 4
- The psychiatric risk profile in women appears substantially lower than in men, but vigilance is warranted given emerging safety signals 11, 12
Clinical Bottom Line for Women
Women tolerate finasteride far better than men, with minimal sexual side effects and only transient headache or mild depression in the first month. 2, 4 The overwhelming safety priority is preventing pregnancy through strict contraception, as teratogenic risk to male fetuses is absolute. 9, 8 Overall, 5-alpha reductase inhibitors are well-tolerated in women but not without risk, highlighting the importance of patient education prior to treatment. 3